[ Investors » Press Releases ]
2008 | 2007 | 2006 | 2005 | 2004
Press Releases
|
PolyMedix Receives SBIR Grants for Biodefense Research |
|
October 5, 2004
Program will study antibiotic compounds for use against anthrax October 5, 2004, Philadelphia, PA: PolyMedix, Inc. announced today that it has received a Phase I SBIR in the amount of $167,000 for biodefense research. Under this grant the Company will study its novel antibiotic compounds against the infectious agent that causes anthrax (Bacillus anthracis) and other biowarfare pathogens.
Read More |
|
Novel PolyMedix Antibiotic Compounds Demonstrate Positive Activity in Animal Testing |
|
September 28, 2004
Unique Mechanism of Action Demonstrates Lack of Susceptibility to Bacterial Resistance
PolyMedix, Inc. announced today that it has demonstrated positive activity in animal testing with its novel small molecule host defense protein mimetic antibiotic compounds. A lead series of compounds has been selected for advancement into development for human clinical trials.
Read More |
|
PolyMedix Antibiotic Compounds Demonstrate Positive Activity Against Anthrax Bacteria |
|
February 20, 2004
PolyMedix, Inc. announced today that its novel antibiotic compounds have demonstrated positive antimicrobial activity in test tube experimental studies against the anthrax bacteria (Bacillus anthracis). In pre-clinical studies conducted at two outside laboratories, several PolyMedix antibiotic compounds were shown to exert potent antimicrobial activity against 12 different clinical and field isolates of anthrax bacteria.
Read More |
|
PolyMedix Raises $2 Million to Date in Ongoing Series B Financing |
|
February 12, 2004
PolyMedix, Inc. announced today that it has raised a total of $2 million to date in a first closing and as part of its ongoing Series B financing efforts. The Company anticipates raising additional funds over the next three months in a second closing of the Series B round. The proceeds will be used to further the development of the Company’s novel antimicrobial compounds and conduct animal testing with lead compounds.
Read More |
|
PolyMedix Appoints Management Team |
|
February 12, 2004
PolyMedix, Inc. announced today appointments of three Vice Presidents of the Company. Richard Scott, Ph.D. is the Company’s new Vice President of Biology Research; Dawn Eringis is PolyMedix’s Vice President of Business Development; and Timothy DiLiberti is the Company’s new Vice President of Drug Development and Regulatory Affairs.
Read More |
Press releases contain forward-looking statements that involve risks and that could cause PolyMedix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these forward-looking statements by using words such as "anticipates," "believes," “hopes,” "estimates," "looks," "expects," "plans," "intends" and similar expressions. Among other things, there can be no assurance that PolyMedix’s compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forwardlooking
statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
return to top ^ |
